WO1994027649A1 - Timbre d'application transdermique, procede et dispositif de fabrication - Google Patents
Timbre d'application transdermique, procede et dispositif de fabrication Download PDFInfo
- Publication number
- WO1994027649A1 WO1994027649A1 PCT/US1994/005861 US9405861W WO9427649A1 WO 1994027649 A1 WO1994027649 A1 WO 1994027649A1 US 9405861 W US9405861 W US 9405861W WO 9427649 A1 WO9427649 A1 WO 9427649A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patch
- tri
- medication
- cutting
- opening
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 239000000463 material Substances 0.000 claims abstract description 92
- 229940079593 drug Drugs 0.000 claims abstract description 63
- 239000003814 drug Substances 0.000 claims abstract description 63
- 239000000126 substance Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000002648 laminated material Substances 0.000 claims description 52
- 239000011148 porous material Substances 0.000 claims description 25
- 239000000853 adhesive Substances 0.000 claims description 14
- 230000001070 adhesive effect Effects 0.000 claims description 14
- 125000006850 spacer group Chemical group 0.000 claims description 9
- 238000007789 sealing Methods 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 abstract description 4
- 239000010410 layer Substances 0.000 description 20
- 239000012528 membrane Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 229920006267 polyester film Polymers 0.000 description 3
- -1 Metrifonat Chemical compound 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- KUEAHAUQRJAQCI-UHFFFAOYSA-J 2,2'-spirobi[1,3,2$l^{4}-benzodioxastibole]-4,4',6,6'-tetrasulfonic acid Chemical compound [Sb+4].OC1=CC(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C1O.OC1=CC(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C1O KUEAHAUQRJAQCI-UHFFFAOYSA-J 0.000 description 1
- WZSPWMATVLBWRS-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;n-(2-methylphenyl)-2-(propylamino)propanamide Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C WZSPWMATVLBWRS-UHFFFAOYSA-N 0.000 description 1
- YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- RDXLYGJSWZYTFJ-UHFFFAOYSA-N Niridazole Chemical compound S1C([N+](=O)[O-])=CN=C1N1C(=O)NCC1 RDXLYGJSWZYTFJ-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 229960003003 biperiden Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005130 niridazole Drugs 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- ZQHYKVKNPWDQSL-KNXBSLHKSA-N phenazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-KNXBSLHKSA-N 0.000 description 1
- 229960000897 phenazocine Drugs 0.000 description 1
- 229960001963 pilocarpine nitrate Drugs 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
- A61F13/0279—Apparatus or processes for manufacturing adhesive dressings or bandages by attaching individual patches on moving webs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/00906—Plasters containing means for transcutaneous or transdermal drugs application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
- A61F2013/0296—Apparatus or processes for manufacturing adhesive dressings or bandages for making transdermal patches (chemical processes excluded)
Definitions
- the present invention relates generally to systems for applying substances and, specifically, to a system, including a patch, for applying transdermally and/or topically deliverable substances such as medications to a localized area of a patient such as a point of irritation, injury, infection and the like while preventing excess medication from being applied to the area, and an apparatus and method for making such a drug delivery system.
- Transdennal drug delivery systems have, in recent years, become an increasingly important means of administering drugs. Such systems offer advantages clearly not achievable by other modes of administration such as avoiding introduction of the drug through the gastro- intestinal tract or punctures in the skin to name a few.
- TTS NitroTM patch A variety of transdennal drug delivery systems or patches are commercially available and well known in the art.
- One such system is known as the TTS NitroTM patch
- Such a patch includes a reservoir containing the medication, which is in the form of a viscous substance.
- the patch also includes a backing material which can be peeled away and discarded prior to topical application of the patch.
- the patch includes a size exclusion membrane covering the medication, which comes in contact with the area to which the patch is applied. The membrane also maintains the medication in the patch and permits passage of the medication througn the membrane into the applied area.
- problems and limitation have been associated with such patches, including limits on the rate of delivery of the medication, i.e., nitroglycerine, as a result of the permeability of the membrane.
- a system including a patch for transdermally and/or topically applying a substance such as a medication can be constructed in accordance with the present invention.
- the patch is easily activated by the user to administer the medication, which can be forced from the patch and located or otherwise situated at the area to be applied.
- Such users may include the patient as well as doctors, nurses and the like.
- the patch of the present invention for applying a substance such as a transdennal medication topically to an applied area includes a first material having a reservoir formed therein, a dosage of medication contained in the reservoir, and a second material covering the reservoir with at least one opening formed therein through which the medication may pass for application to the applied area.
- the patch also includes a porous material situated between the second material and the dose of medication.
- the porous material may include a layer of non-woven material.
- the second material includes a layer of an adhesive material and a release liner covering the layer of adhesive material with the adhesive material sandwiched between the release liner and the diaphragm, with at least either the first material or the second material includes a heat seal coating.
- the reservoir is defined by a dimple formed in the first material with a cavity therein.
- the second material includes a diaphragm and wherein the at least one opening includes a plurality of slits formed in the diaphragm.
- the method of the present invention of making a patch for topically applying a substance to an applied area of a patient includes the steps of forming a reservoir in a backing material, cutting at least one opening in at least a portion of a tri-laminate material, placing a dose of medication on the tri-laminate material approximate the at least one opening, sealing the backing material and the tri- laminate material together to form a continuous web, and cutting a patch from the web.
- the method also includes the step of placing a porous material between the tri- laminate material and the backing material prior to placing the dose of medication on the tri-laminate material so that the porous material is situated between the dose of medication and the tri-laminate material, with the porous material including feeding a layer of non-woven material therebetween.
- the step of sealing the backing material to the tri-laminate material incudes the step of forming a heat seal around a periphery of the reservoir.
- the step of cutting the patches from the continuous web includes die cutting and the step of forming the reservoir in the backing material includes applying a positive pressure to one side of the backing material.
- the step of cutting the opening in the tri-laminate material includes cutting a plurality of slits in a diaphragm.
- the apparatus of the present invention for making a patch for applying a substance to an applied area of a patient includes means for forming a reservoir in a backing material, means for cutting at least one opening in a first layer of a tri-laminate material, means for placing at least one dose of medication on the tri-laminate material, means for sealing the backing material and the tri-laminate material together to form a continuous web, and means for cutting a patch from the continuous web.
- the apparatus also includes means for placing a porous material between the tri-laminate material and the dose of medication, with the means for placing the porous material including means for applying a layer of a non-woven material to the tri-laminate material before placing the dose of medication thereon.
- the means for cutting the at least one opening includes a bracket assembly and a pair of spacers. Also, the means for cutting the at least one opening is adapted to include at least one adjustment screw for adjusting the cutting edge of the blade.
- the bracket assembly includes at least one blade having a cutting edge for cutting the at least one opening in the first layer of material.
- an extending portion of the pair of spacers is aligned with the cutting edge of the blade to limited advancement of the cutting edge and the corresponding depth of the opening in the tri-laminate material.
- Figure 1 is a perspective schematic view of the apparatus of the system of the present invention illustrating the various steps for making the patches;
- Figure 2 is a cross-sectional, side view of the sub- assembly for forming the reservoir or dimple in the patch;
- Figure 3 is a cross-sectional, side view of the sub- assembly for forming at least one opening in the diaphragm or barrier of the patch;
- Figure 4 is an enlarged, fragmentary view of the sub- assembly illustrated in Figure 2;
- Figure 5 is an enlarged, fragmentary view of the sub- assembly illustrated in Figure 3, and Figure 5A is an exploded perspective view of the bracket assembly for holding one or more blades for forming slits;
- Figure 6 is a perspective view of the patch of the present invention.
- Figure 7 is a perspective bottom view of the patch illustrated in Figure 6;
- Figure 8 is an enlarged, cross-sectional, side view of the patch illustrated in Figure 6;
- FIG. 9 is an enlarged, fragmentary view of the patch illustrated in Figure 6 showing removal of the release liner
- Figure 10 is an enlarged, fragmentary view of the patch illustrated in Figure 6 showing removal of the release liner with the medication being released or otherwise forced through each opening in the diaphragm from the reservoir;
- Figure 11 is a logic flow diagram depicting the various steps for the method of making the patch of the present invention.
- Figure 12 is a perspective schematic view of the preferred embodiment of the apparatus of the system of the present invention illustrating the various steps for making the patches, including the step of applying a porous material such as a layer of non-woven material to the tri- laminate material prior to placing the dose of medication thereon
- Figure 12A is a perspective view of the bracket assembly for holding the cutter for forming the opening by kiss-cutting the first layer of the tri-laminate material
- Figure 13 is a perspective schematic view of an alternative embodiment of the apparatus of the system of the present invention illustrating the various steps for making the patches, including the step of placing a disc-shaped piece of a porous material on the tri-laminate material prior to placing the dose of medication thereon;
- Figure 14 is an enlarged, cross-sectional, side view of the patch of the present invention with the layer of non- woven material situated between the tri-laminate material and the dose of medication;
- Figure 15 is an enlarged, cross-sectional, side view of the patch of the present invention with the disc-shaped piece of porous material situated between the tri-laminate material and the dose of medication.
- the various embodiments of the system of the present invention for applying a substance to an applied area are illustrated in Figures 1-15, with the apparatus generally designated as 10 and the patches generally designated as 11.
- the apparatus 10 of the present invention includes a number of sub-assemblies 12, 14, 16, 18 and 20 for forming a backing material 52 and a tri-laminate material 54 into a continuous web 56 from which the patches 11 are cut.
- the apparatus includes a sub-assembly 12 for forming a reservoir 62 in the backing material 52, a sub- assembly 14 for forming at least one opening 64 in one layer of the tri-laminate material to provide a passage for the substance to be applied, a sub-assembly 16 for placing a dose of the substance such as a medication 66 on the tri- laminate material, a sub-assembly 18 for sealing the backing material and tri-laminate material together with the medication therebetween into the continuous web 56, and a final sub-assembly 20 for cutting the patches 11 from the continuous web.
- a sub-assembly 12 for forming a reservoir 62 in the backing material 52
- a sub- assembly 14 for forming at least one opening 64 in one layer of the tri-laminate material to provide a passage for the substance to be applied
- a sub-assembly 16 for placing a dose of the substance such as a medication 66 on the tri- laminate material
- the backing material 52 forming one portion of the continuous web is preferably a 2-3 mil thick sheet of Scotch PackTM film available from Minnesota Mining and Manufacturing Company ("3M"), St. Paul, Minnesota.
- the tri-laminate material 54 forming the other portion of the continuous web may include a diaphragm or barrier material 68 for covering the reservoir 62, such as a 3 mil thick sheet of 9% EVA or treated polyester membrane material, a layer of adhesive 70, such as silicone, acrylic or MA 24TM adhesive, and a 1-2 mil thick sheet of polyester film 72 for covering the patch, such as coated polyester with a silicone release coating thereon and a heat seal coating available from Adhesive Research, Glennrock, Pennsylvania.
- the sub-assembly 12 for forming the reservoir includes a bottom plate 22 and a top plate 24 mounted to a frame 25, with at least one of the plates being movable in the vertical direction relative to the other plate. At least one channel 26 is formed in the bottom plate 22, and a cavity 28 is formed in the top plate 24, with a number of connecting channels 30 in communication with the cavity and the atmosphere.
- the backing material passes between the plates 22, 24, which can be brought together by an actuating cylinder and a positive pressure provided through channel 26 against the backing material to force the backing material into the cavity beyond the point of elasticity of the backing material to permanently form a dimple or blister in the backing material, with the amount of pressure being applied depending upon the elastic strength of the backing material, which in the case of the preferred material is 40 to 80 PSI.
- a vacuum may be drawn on the opposite side of the backing material to facilitate forming of the reservoir.
- the sub-assembly 14 for forming the opening 64 in the tri-laminate material 54 includes a bottom plate 32 and a top plate 34 mounted to a frame 35, with at least one of the plates being movable relative to the other by an actuating cylinder 31A.
- a bracket assembly 36 is attached to the top plate 34 for holding at least one blade 38, and a pair of spacers 40A and 40B is attached along the sides of the bracket assembly to the frame 35 for limiting advancement of the blade in the tri-laminate material, with the blade 38 being of generally T-shape.
- the bracket assembly 36 is mounted to the top plate 34 and includes a face plate 42, a blade holder 43 and a backing plate 44.
- the face plate 42 may include a plurality of slits 45A and the blade holder may include a plurality of slits 45B, with the slits 45A and 45B sized to accept each blade therein.
- each could include slits corresponding to the number of blades utilized.
- An upper portion 38A of each blade 38 rests against an upper surface 43A of the blade holder 43, with a lower portion 38B of the blade having the cutting edge thereon extending through the face plate 42 to come in contact with the diaphragm 68. In this way, the upper portions 38A of each blade 38 can be ground to provide a level surface in contact with the backing plate 44.
- the bracket assembly 36 and the spacers 38A and 38B are adjustable by means of a number of screws 46.
- a dose of medication is applied to the tri-laminate material above the opening 64 previously cut in the diaphragm 68 by sub-assembly 16 as is well known in the art, which in the preferred embodiment includes a positive displacement pump.
- the dose of medication can be varied depending upon the substance used, which may, for example, include a cream which can take the pain out of getting vaccinations and other needle sticks such as EMLATM (Eutectic Moisture of Local Anesthetics) Cream in the form of a combination of lidocaine and prilocaine in an oil and water emulsion and commercially available from Astra, Sweden.
- the backing material and the tri-laminate material are brought together and heat sealed around the outer periphery of the dimple by sub-assembly 18 to form the continuous web 56, with each dose of medication being sealed within a corresponding dimple to form the reservoir 62.
- the continuous web is die cut to fabricate the patches 11 therefrom.
- a layer of porous material 58 is feed by sub-assembly 21 between the layer of backing material 52 and the layer of tri-laminate material 54 prior to sub-assembly 16 placing the dose of medication on the web 56A.
- the sub-assembly 14 for forming the opening in the tri-laminate material is modified to include a single blade or circular cutter 48 having a kiss cut die shape as illustrated in Figure 12A.
- At least one circular opening 64A is formed in the diaphragm 68 which corresponds to the opening of the cavity 28 of the reservoir 62 to permit passage of the medication from the reservoir 62 through the porous material 58 when the release liner 72 is peeled away from the patch 11A.
- the porous material is preferably a non-woven, heat- sealable polymeric material, such as for example, non-woven LDPE available from Poly-Bond, Inc., Waynesboro, Virginia.
- the layer of non-woven material 58 can be feed along one of the tracks of the apparatus 10A and applied as an integral part of the web 56A from which the patches 11A illustrated in Figure 14 is cut, and the non-woven material 58 holds the medication back when the sheet of polyester film is peeled away from the patch.
- a disc-shaped piece of porous material 60 is placed by sub-assembly 21A on the layer of tri-laminate material 54 prior to sub-assembly 16 placing the dose of medication on the web 56B.
- the sub-assembly 14 for forming the opening in the tri-laminate material is also modified as in the case of the preferred embodiment previously discussed with respect to Figure 12A so that at least one circular opening 64A is formed which corresponds to the opening of the cavity 28 of the reservoir 62, which can likewise be peeled away with the release liner.
- the disc-shaped piece of porous material 60 may include surgical gauze or a like material.
- the disc 60 holds the medication back when the sheet of polyester film is peeled away from the patch 11B illustrated in Figure 15.
- the material of which the diaphragm 68 is made in the various embodiments is spaced from the edge of the release liner to provide a free zone 73 without adhesive, with the spacers 40A, 40B and the cutting edge of each blade 38 or the cutter 48 being aligned such that when the top plate 34 and the bottom plate 32 are brought together with the tri- laminate material therebetween, extending portions 41A, 41B of the spacers come in contact with the release liner along the free zone 73 and do not come in contact with the material from which the diaphragm is made.
- a cutter 48 as illustrated in Figure 12A is preferred to form the circular opening by kiss-cutting the diaphragm material to form a circular slit surrounding a plug of diaphragm material. In this way, upon use of the patch, the plug of diaphragm covering the reservoir and porous material adhered to the adhesive is peeled away with the release liner to expose the opening.
- blades 38 having straight cutting edges may be used to form the openings as straight- slits so that upon use of the patch, the diaphragm remains and covers the reservoir which might otherwise adhere to the adhesive and peel away with the release liner.
- the openings 64 may take other forms and shapes depending upon the application as well as the viscosity of the medication. For example, where the medication is a semi-rigid gel or hydrogel, the openings may merely be a single opening exposing either the complete reservoir or the porous material upon peeling the release liner from the patch.
- the materials and components used for constructing the various sub-assemblies are not essential to the present invention and may be made from a variety of commercially available components well known to those skilled in the art. Normally, manufacturers of the present apparatus and patch will select the various materials and components, based upon price, availability and application.
- the upper sheet of material of the tri-laminate may include any polymeric material or a membrane material.
- the backing material 52 and the tri- laminate material 54 are processed through the apparatus 10 along separate tracks through the sub-assembly 12 for forming the reservoir and the sub-assembly 14 for forming the openings in the diaphragm 68, with the dose of medication being applied to the tri-laminate material above the openings or by kiss-cutting. Thereafter, the two materials 52, 54 are brought together with the backing material 52 also overlapping the diaphragm 68 about the free zone and heat sealed by the sub-assembly 18 to form the continuous web 56 from which the patches 11 are die cut, which in the preferred embodiment ' includes a tab 74 extending into the free zone 73 for gripping and peeling the patch apart.
- the layer of porous material 58 includes a non-woven material of a polymeric material which may be feed along the same track as the tri-laminate to situate the layer of non-woven material on the tri-laminate material 54 prior to placing the dose of medication on the web so that the non-woven material is situated between the medication and the tri- laminate as an integral layer of the web for heat sealing the backing material, tri-laminate material and non-woven material together and cutting the various patches 11A therefrom.
- the non-woven material 58 holds the medication in place while the release liner is peeled from the patch for application of the medication to the applied area of the patient. In the way, the medication can then be forced through the non-woven material and applied to the patient.
- the patch is gripped by the tab 74 and pulled to remove the release liner 72 and to expose the medication for topical application.
- a plurality of openings 64 in the form of slits are formed in the diaphragm parallel to the direction of peeling the release liner from the patch.
- the medication may be at least partially forced through the slits when the release liner is peeled from the patch to provide more intimate contact with the area to which the patch is to be applied and without tearing or ripping of the diaphragm as a result of the adhesive.
- the adhesive may be selected so that at least a portion remains on the diaphragm to increase adherence to the area, such as the skin of a patient, surrounding the area to which the medication is to be applied.
- the patch of the present invention can be fabricated or otherwise cut from' the continuous web in a number of shapes other than that shown in the drawings. Also, the patch can be made in different sizes depending upon whether it is to be used by adults or infants.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Manufacturing & Machinery (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/549,747 US5851549A (en) | 1994-05-25 | 1994-05-25 | Patch, with system and apparatus for manufacture |
AU69575/94A AU6957594A (en) | 1993-05-26 | 1994-05-25 | Patch, with system and apparatus for manufacture |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6763893A | 1993-05-26 | 1993-05-26 | |
US08/067,638 | 1993-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994027649A1 true WO1994027649A1 (fr) | 1994-12-08 |
Family
ID=22077362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/005861 WO1994027649A1 (fr) | 1993-05-26 | 1994-05-25 | Timbre d'application transdermique, procede et dispositif de fabrication |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6957594A (fr) |
WO (1) | WO1994027649A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6375990B1 (en) | 1997-10-09 | 2002-04-23 | Emory University | Method and devices for transdermal delivery of lithium |
EP2113250A1 (fr) * | 2008-02-06 | 2009-11-04 | Nitto Denko Corporation | Structure d'emballage de patch |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4556441A (en) * | 1983-01-24 | 1985-12-03 | Faasse Jr Adrian L | Pharmaceutical packaging method |
US5122127A (en) * | 1985-05-01 | 1992-06-16 | University Of Utah | Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues |
US5234690A (en) * | 1991-08-23 | 1993-08-10 | Cygnus Therapeutic Systems | Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset |
US5244677A (en) * | 1988-12-29 | 1993-09-14 | Minnesota Mining And Manufacturing Company | Application system for drug containing microemulsions |
US5273756A (en) * | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset |
-
1994
- 1994-05-25 WO PCT/US1994/005861 patent/WO1994027649A1/fr active Application Filing
- 1994-05-25 AU AU69575/94A patent/AU6957594A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4556441A (en) * | 1983-01-24 | 1985-12-03 | Faasse Jr Adrian L | Pharmaceutical packaging method |
US5122127A (en) * | 1985-05-01 | 1992-06-16 | University Of Utah | Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues |
US5244677A (en) * | 1988-12-29 | 1993-09-14 | Minnesota Mining And Manufacturing Company | Application system for drug containing microemulsions |
US5234690A (en) * | 1991-08-23 | 1993-08-10 | Cygnus Therapeutic Systems | Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset |
US5273756A (en) * | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6375990B1 (en) | 1997-10-09 | 2002-04-23 | Emory University | Method and devices for transdermal delivery of lithium |
EP2113250A1 (fr) * | 2008-02-06 | 2009-11-04 | Nitto Denko Corporation | Structure d'emballage de patch |
CN101503132B (zh) * | 2008-02-06 | 2011-09-28 | 日东电工株式会社 | 贴片包装结构 |
Also Published As
Publication number | Publication date |
---|---|
AU6957594A (en) | 1994-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5851549A (en) | Patch, with system and apparatus for manufacture | |
KR100348948B1 (ko) | 국부드레싱,국부드레싱의제조방법및국부드레싱의용도 | |
US6059913A (en) | Method for producing transdermal patches (TTS) | |
US5679373A (en) | Process of assembling a transdermal patch incorporating a polymer film incorporated with an active agent | |
US4822617A (en) | Drug delivery device | |
JP2571563B2 (ja) | 経皮パツチ | |
JP5330832B2 (ja) | 両面非接着剥離フィルム | |
EP2316437B1 (fr) | Système d'administration de médicaments multicouche avec protection contre le flux de matériaux du réservoir | |
AU5341690A (en) | Device for administering an active agent to the skin or mucosa | |
WO1994009848A1 (fr) | Systeme de transfert de substance destine a l'application topique | |
MXPA96004352A (en) | Topical bandage, method of manufacturing of topical unvendage and use of a bandage top | |
IL91123A (en) | A multi-layered plaster | |
US6315854B1 (en) | Transdermal therapeutic plaster | |
HRP920828A2 (hr) | Flaster s aktivnom tvari za kontrolirano nanošenje aktivne tvari na kožu | |
US4664736A (en) | Pharmaceutical packaging method | |
WO1994027649A1 (fr) | Timbre d'application transdermique, procede et dispositif de fabrication | |
CS261105B1 (cs) | Transdermální terapeutický systém |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08549747 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |